Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.

× No keyword cloud information.

31 in total

1. Surgical removal of subfoveal choroidal neovascularisation in highly myopic patients.

Authors: J M Ruiz-Moreno; C de la Vega
Journal: Br J Ophthalmol Date: 2001-09 Impact factor: 4.638

2. Initial experience of inferior limited macular translocation for subfoveal choroidal neovascularization resulting from causes other than age-related macular degeneration.

Authors: G Y Fujii; M S Humayun; D J Pieramici; A P Schachat; K G Au Eong; E de Juan
Journal: Am J Ophthalmol Date: 2001-01 Impact factor: 5.258

3. Does lesion size determine the success rate of photodynamic therapy for age-related macular degeneration?

Authors: S Sivaprasad; G M Saleh; H Jackson
Journal: Eye (Lond) Date: 2006-01 Impact factor: 3.775

4. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial--VIP report no. 1.

Authors:
Journal: Ophthalmology Date: 2001-05 Impact factor: 12.079

5. A preliminary study of photodynamic therapy using verteporfin for choroidal neovascularization in pathologic myopia, ocular histoplasmosis syndrome, angioid streaks, and idiopathic causes.

Authors: M Sickenberg; U Schmidt-Erfurth; J W Miller; C J Pournaras; L Zografos; B Piguet; G Donati; H Laqua; I Barbazetto; E S Gragoudas; A M Lane; R Birngruber; H van den Bergh; H A Strong; U Manjuris; T Gray; M Fsadni; N M Bressler
Journal: Arch Ophthalmol Date: 2000-03

6. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma.

Authors: A Ferrario; K F von Tiehl; N Rucker; M A Schwarz; P S Gill; C J Gomer
Journal: Cancer Res Date: 2000-08-01 Impact factor: 12.701

7. Long-term visual acuity after argon green laser photocoagulation of juxtafoveal choroidal neovascularization in highly myopic eyes.

Authors: J M Ruiz-Moreno; J A Montero
Journal: Eur J Ophthalmol Date: 2002 Mar-Apr Impact factor: 2.597

8. Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.

Authors: Richard F Spaide; John Sorenson; Leandro Maranan
Journal: Ophthalmology Date: 2003-08 Impact factor: 12.079

9. Verteporfin photodynamic therapy in highly myopic subfoveal choroidal neovascularisation.

Authors: J A Montero; J M Ruiz-Moreno
Journal: Br J Ophthalmol Date: 2003-02 Impact factor: 4.638

10. Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes.

Authors: J M Ruiz-Moreno; J A Montero
Journal: Br J Ophthalmol Date: 2003-07 Impact factor: 4.638

6 in total

1. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses.

Authors: Jose M Ruiz-Moreno; Javier A Montero; Pedro Amat-Peral
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2011-01-14 Impact factor: 3.117

2. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.

Authors: Lazaros Konstantinidis; Irmela Mantel; Jean-Antoine C Pournaras; Leonidas Zografos; Aude Ambresin
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2008-11-29 Impact factor: 3.117

3. Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia.

Authors: Pukhraj Rishi; Ekta Rishi; Anusha Venkataraman; Lingam Gopal; Tarun Sharma; Muna Bhende; Dhanashree Ratra; Pratik Ranjan Sen; Parveen Sen
Journal: Indian J Ophthalmol Date: 2011 May-Jun Impact factor: 1.848

Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study.